Vertex Pharmaceuticals (VRTX) Other Accumulated Expenses (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Other Accumulated Expenses of $407.1 million for Q1 2026, up 5.36% year-over-year from $386.4 million in Q1 2025, and down 4.95% quarter-over-quarter from $428.3 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Other Accumulated Expenses (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Other Accumulated Expenses history runs 18 years deep, the most recent figure standing at $407.1 million for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 5.36% year-over-year to $407.1 million; the TTM figure through Mar 2026 stood at $407.1 million (up 5.36% YoY), while the FY2025 annual figure was $428.3 million, up 17.99% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $407.1 million, down from $428.3 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $648.6 million in Q1 2024, with the low at $218.0 million in Q3 2022.
- The 5-year median for Other Accumulated Expenses is $377.0 million (2023), against an average of $376.6 million.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses surged 72.04% in 2024, then sank 40.43% in 2025.
- Vertex Pharmaceuticals' Other Accumulated Expenses stood at $311.5 million in 2022, then soared by 69.25% to $527.2 million in 2023, then slumped by 31.15% to $363.0 million in 2024, then advanced by 17.99% to $428.3 million in 2025, then retreated by 4.95% to $407.1 million in 2026.
- Business Quant data shows VRTX's Other Accumulated Expenses at $407.1 million in Q1 2026, $428.3 million in Q4 2025, and $441.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 329.40 Mn |
| Mar 31, 2026 | 407.10 Mn |
| Dec 31, 2025 | 428.30 Mn |
| Sep 30, 2025 | 441.50 Mn |
| Jun 30, 2025 | 425.40 Mn |
| Mar 31, 2025 | 386.40 Mn |
| Dec 31, 2024 | 363.00 Mn |
| Sep 30, 2024 | 357.60 Mn |
| Jun 30, 2024 | 279.30 Mn |
| Mar 31, 2024 | 648.60 Mn |
| Dec 31, 2023 | 527.20 Mn |
| Sep 30, 2023 | 316.20 Mn |
| Jun 30, 2023 | 391.00 Mn |
| Mar 31, 2023 | 377.00 Mn |
| Dec 31, 2022 | 311.50 Mn |
| Sep 30, 2022 | 218.00 Mn |
| Jun 30, 2022 | 238.70 Mn |
| Mar 31, 2022 | 286.10 Mn |
| Dec 31, 2021 | 268.40 Mn |
| Sep 30, 2021 | 201.41 Mn |